Skip to main content

Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.

Publication ,  Journal Article
Reardon, DA; Wen, PY; Desjardins, A; Batchelor, TT; Vredenburgh, JJ
Published in: Expert Opin Biol Ther
April 2008

BACKGROUND: Adults with malignant glioma, especially the most common subtype, glioblastoma multiforme, have an unacceptably poor outcome with current therapies. Malignant gliomas are amongst the most angiogenic of cancers, and VEGF is the dominant angiogenic mediator in these tumors. OBJECTIVE: To summarize the clinical experience of VEGF-directed treatment for malignant glioma. METHODS: We reviewed the completed, ongoing and planned clinical trials evaluating anti-VEGF strategies for malignant glioma patients. RESULTS/CONCLUSIONS: Recent studies incorporating anti-VEGF agents plus cytotoxic therapy among recurrent malignant glioma patients have achieved unprecedented improvements in radiographic response, time to progression and survival. Furthermore, acceptable toxicity was observed. Hence, a major current focus in neuro-oncology is to further develop antiangiogenic strategies for this desperate patient population.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Expert Opin Biol Ther

DOI

EISSN

1744-7682

Publication Date

April 2008

Volume

8

Issue

4

Start / End Page

541 / 553

Location

England

Related Subject Headings

  • Vascular Endothelial Growth Factor A
  • Treatment Outcome
  • Signal Transduction
  • Neovascularization, Pathologic
  • Middle Aged
  • Male
  • Immunology
  • Humans
  • Glioblastoma
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Reardon, D. A., Wen, P. Y., Desjardins, A., Batchelor, T. T., & Vredenburgh, J. J. (2008). Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther, 8(4), 541–553. https://doi.org/10.1517/14712598.8.4.541
Reardon, David A., Patrick Y. Wen, Annick Desjardins, Tracy T. Batchelor, and James J. Vredenburgh. “Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.Expert Opin Biol Ther 8, no. 4 (April 2008): 541–53. https://doi.org/10.1517/14712598.8.4.541.
Reardon DA, Wen PY, Desjardins A, Batchelor TT, Vredenburgh JJ. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther. 2008 Apr;8(4):541–53.
Reardon, David A., et al. “Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.Expert Opin Biol Ther, vol. 8, no. 4, Apr. 2008, pp. 541–53. Pubmed, doi:10.1517/14712598.8.4.541.
Reardon DA, Wen PY, Desjardins A, Batchelor TT, Vredenburgh JJ. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther. 2008 Apr;8(4):541–553.

Published In

Expert Opin Biol Ther

DOI

EISSN

1744-7682

Publication Date

April 2008

Volume

8

Issue

4

Start / End Page

541 / 553

Location

England

Related Subject Headings

  • Vascular Endothelial Growth Factor A
  • Treatment Outcome
  • Signal Transduction
  • Neovascularization, Pathologic
  • Middle Aged
  • Male
  • Immunology
  • Humans
  • Glioblastoma
  • Female